Related Experiment Video
Updated: Jan 8, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal
Thatiany Souza Marinho1, Julie Oliveira A Bittencourt1, Marcia Barbosa Aguila1
1Laboratory of Morphometry, Metabolism, and Cardiovascular Disease, Biomedical Center, Institute of Biology, The State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Abstract:
Obesity, diabetes, and menopause impair hypothalamic regulation of energy balance by inducing inflammation, cellular stress, and disruption of neuropeptide signaling. In a female mouse model combining these conditions, we investigated whether tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, restores hypothalamic homeostasis by integrating gene and protein expression analyses. Ovariectomized and sham-operated mice were fed either a control or high-fat, high-sucrose diet and then treated with tirzepatide for four weeks. Metabolic and hormonal stress induced robust activation of inflammatory pathways, elevated cytokine and chemokine expression, marked endoplasmic reticulum stress, and enhanced microglial reactivity, accompanied by a shift toward appetite-stimulating neuropeptides and reduced expression of appetite-suppressing neuropeptides. Tirzepatide produced broad hypothalamic benefits, markedly suppressing inflammatory and stress-related markers, reprogramming microglia toward an anti-inflammatory phenotype, and restoring neuropeptide balance by reducing agouti-related peptide and neuropeptide Y while increasing proopiomelanocortin and melanocortin 4 receptor expression. Treatment also lowered suppressor of cytokine signaling 3 and normalized doublecortin expression, indicating enhanced neuronal plasticity and recovery of hypothalamic circuitry. Multivariate analysis demonstrated that tirzepatide shifted the overall hypothalamic molecular profile of obese-diabetic and ovariectomized mice to that of control groups, highlighting coordinated improvement across inflammatory, glial, and neuropeptidergic pathways. In conclusion, these findings show that tirzepatide exerts potent and broad central nervous system actions capable of counteracting hypothalamic inflammation, cellular stress, microglial activation, and neuropeptide dysregulation under severe metabolic-hormonal challenge, supporting its therapeutic potential to restore hypothalamic integrity and metabolic control in obesity and diabetes during menopause.
Insights
Tirzepatide effectively counteracts hypothalamic dysfunction caused by obesity, diabetes, and menopause. This drug restores neural pathways and neuropeptide balance, offering therapeutic potential for metabolic control.
Area of Science:
- Neuroendocrinology
- Metabolic disease research
- Pharmacology
Background:
- Obesity, diabetes, and menopause disrupt hypothalamic energy balance via inflammation and stress.
- These conditions alter neuropeptide signaling, impacting appetite regulation.
- Existing treatments often fail to address the complex hypothalamic changes.
Purpose of the Study:
- To investigate tirzepatide's ability to restore hypothalamic homeostasis in a mouse model of combined metabolic and hormonal stress.
- To analyze the molecular mechanisms by which tirzepatide impacts hypothalamic inflammation, cellular stress, and neuropeptide signaling.
Main Methods:
- Utilized a female mouse model with ovariectomy and high-fat, high-sucrose diet to simulate obesity, diabetes, and menopause.
- Administered tirzepatide (dual GIP/GLP-1 receptor agonist) for four weeks.
- Integrated gene and protein expression analyses, including cytokine, chemokine, and neuropeptide profiling, alongside microglial and neuronal marker assessments.
Main Results:
- Tirzepatide significantly reduced hypothalamic inflammation, endoplasmic reticulum stress, and microglial activation.
- The drug normalized neuropeptide balance, decreasing appetite stimulants (agouti-related peptide, neuropeptide Y) and increasing appetite suppressors (proopiomelanocortin, melanocortin 4 receptor).
- Tirzepatide enhanced neuronal plasticity markers and shifted the overall hypothalamic molecular profile towards a healthy state.
Conclusions:
- Tirzepatide demonstrates potent central nervous system actions to counteract hypothalamic inflammation and stress.
- The drug effectively restores hypothalamic integrity and neuropeptide signaling disrupted by metabolic and hormonal challenges.
- These findings support tirzepatide's therapeutic potential for managing obesity and diabetes, particularly during menopause.
More Related Videos
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Related Concept Videos
Menopause
Hypothalamic-Pituitary Axis
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Regulation of Food Intake
Hormonal Regulation
Hormonal Regulation